4DMedical Limited

ASX:4DX Stock Report

Market Cap: AU$1.3b

4DMedical Future Growth

Future criteria checks 2/6

4DMedical is forecast to grow earnings and revenue by 45.7% and 68.6% per annum respectively. EPS is expected to grow by 54.6% per annum. Return on equity is forecast to be 2.8% in 3 years.

Key information

45.7%

Earnings growth rate

54.65%

EPS growth rate

Healthcare Services earnings growth23.9%
Revenue growth rate68.6%
Future return on equity2.84%
Analyst coverage

Low

Last updated03 Dec 2025

Recent future growth updates

Recent updates

User avatar

Acquisitions, Philips Partnerships And FDA Approvals Will Expand Market Reach

Strategic acquisitions, partnerships, and regulatory approvals are poised to enhance market presence, revenue, and net margins through expanded distribution and high-margin services.

Here's Why We're Watching 4DMedical's (ASX:4DX) Cash Burn Situation

Sep 21
Here's Why We're Watching 4DMedical's (ASX:4DX) Cash Burn Situation

We're Keeping An Eye On 4DMedical's (ASX:4DX) Cash Burn Rate

May 08
We're Keeping An Eye On 4DMedical's (ASX:4DX) Cash Burn Rate

4DMedical Limited's (ASX:4DX) CEO Compensation Is Looking A Bit Stretched At The Moment

Oct 26
4DMedical Limited's (ASX:4DX) CEO Compensation Is Looking A Bit Stretched At The Moment

Here's Why We're Not At All Concerned With 4DMedical's (ASX:4DX) Cash Burn Situation

Jun 16
Here's Why We're Not At All Concerned With 4DMedical's (ASX:4DX) Cash Burn Situation

We Think 4DMedical (ASX:4DX) Needs To Drive Business Growth Carefully

Feb 01
We Think 4DMedical (ASX:4DX) Needs To Drive Business Growth Carefully

Is 4DMedical (ASX:4DX) In A Good Position To Deliver On Growth Plans?

Oct 18
Is 4DMedical (ASX:4DX) In A Good Position To Deliver On Growth Plans?

We're Hopeful That 4DMedical (ASX:4DX) Will Use Its Cash Wisely

Jul 05
We're Hopeful That 4DMedical (ASX:4DX) Will Use Its Cash Wisely

We Think 4DMedical (ASX:4DX) Can Afford To Drive Business Growth

Jan 27
We Think 4DMedical (ASX:4DX) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About 4DMedical's (ASX:4DX) Cash Burn Situation

Jun 05
Here's Why We're Not Too Worried About 4DMedical's (ASX:4DX) Cash Burn Situation

Earnings and Revenue Growth Forecasts

ASX:4DX - Analysts future estimates and past financials data (AUD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/202859-3-333
6/30/202732-19-15-143
6/30/20269-30-30-263
6/30/20256-30-36-34N/A
3/31/20256-35-34-32N/A
12/31/20246-40-32-30N/A
9/30/20245-38-32-31N/A
6/30/20244-36-32-31N/A
3/31/20242-33-33-32N/A
12/31/20231-31-34-32N/A
9/30/20231-31-29-28N/A
6/30/20231-31-24-23N/A
3/31/20231-30-19-18N/A
12/31/20221-28-15-13N/A
9/30/20221-26-22-19N/A
6/30/20221-25-29-25N/A
3/31/20221-23-28-24N/A
12/31/20210-21-26-23N/A
9/30/20210-21-21-19N/A
6/30/20210-21-15-15N/A
3/31/20210-26-16-15N/A
12/31/20200-30-16-15N/A
9/30/20201-26-12-11N/A
6/30/20201-22-9-8N/A
3/31/20202-16-8-7N/A
12/31/20192-9-7-6N/A
9/30/20191-8-7-6N/A
6/30/20191-6-7-6N/A
6/30/20181-4N/A-3N/A
6/30/20171-4N/A-2N/A
12/31/20150-1N/A-1N/A
12/31/201400N/A0N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 4DX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 4DX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 4DX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 4DX's revenue (68.6% per year) is forecast to grow faster than the Australian market (5.9% per year).

High Growth Revenue: 4DX's revenue (68.6% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 4DX's Return on Equity is forecast to be low in 3 years time (2.8%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/15 20:59
End of Day Share Price 2025/12/15 00:00
Earnings2025/06/30
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

4DMedical Limited is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John HesterBell Potter
ZheWei SimJefferies LLC
Thomas GodfreyOrd Minnett Limited